Search research articles
Contact Us
Filters
Showing results (291-300 of 346) with videos related to
Page
of 35
Sort By:
International Journal of Cancer
|
March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
Jens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Blood
|
June 29, 2010
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
Arnt V Kristen, Evangelos Giannitsis, Stephanie Lehrke, et al.
Oncotarget
|
November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
Michael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Blood Advances
|
June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT
Joseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Plos One
|
May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion
Markus Munder, Melanie Engelhardt, Diana Knies, et al.
European Journal of Haematology
|
September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients
Sabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Haematologica
|
May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
Ute Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Hemasphere
|
September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Journal of the American College of Cardiology
|
August 14, 2012
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers
Sebastian J Buss, Mostafa Emami, Derliz Mereles, et al.
Frontiers in Immunology
|
January 30, 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Jean-Marc Hoffmann, Maria-Luisa Schubert, Lei Wang, et al.
Page
of 35
Search research articles
Search
Showing results (291-300 of 346) with videos related to
Sort By:
Page
of 35
International Journal of Cancer
|
March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
Jens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Blood
|
June 29, 2010
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
Arnt V Kristen, Evangelos Giannitsis, Stephanie Lehrke, et al.
Oncotarget
|
November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
Michael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Blood Advances
|
June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT
Joseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Plos One
|
May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion
Markus Munder, Melanie Engelhardt, Diana Knies, et al.
European Journal of Haematology
|
September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients
Sabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Haematologica
|
May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
Ute Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Hemasphere
|
September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Journal of the American College of Cardiology
|
August 14, 2012
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers
Sebastian J Buss, Mostafa Emami, Derliz Mereles, et al.
Frontiers in Immunology
|
January 30, 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Jean-Marc Hoffmann, Maria-Luisa Schubert, Lei Wang, et al.
Page
of 35